1 Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Hydroxychloroquine in Healthy

- 2 Volunteers
- 3 Y.A. de Reus¹, P. Hagedoorn², M.G.G. Sturkenboom³, F.Grasmeijer^{2,4}, M.S. Bolhuis³, I. Sibum², H.A.M.
- 4 Kerstjens¹, H.W. Frijlink², O.W. Akkerman^{1,5*}
- ¹ University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases
- 6 and Tuberculosis, Groningen, the Netherlands
- 7 ² University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen,
- 8 the Netherlands
- 9 ³ University of Groningen, University Medical Center Groningen, Groningen, Department of Clinical
- 10 Pharmacy and Pharmacology, the Netherlands
- ⁴ PureIMS B.V., Roden, the Netherlands
- ⁵ University of Groningen, University Medical Center Groningen, TB center Beatrixoord, Groningen,
- 13 the Netherlands
- 14
- 15 *Corresponding author

Onno W. Akkerman, MD, PhD

University Medical Center Groningen

PO Box 30001, 9700 RB Groningen, the Netherlands

e-mail: o.w.akkerman@umcg.nl

phone: +31 50 3610857

16

- 17 Word count abstract: 200
- 18 Word count full text: 3052
- 19 **Keywords:** SARS-CoV-2, covid-19, hydroxychloroquine, inhalation

21 ABSTRACT

С	ъ
Z	Z

23 Rationale:

- 24 Inhaled antimicrobials enable high local concentrations where needed and, compared to orally
- administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections,
- hydroxychloroquine (HCQ) administered as dry powder via inhalation could be safer than oral HCQ
- 27 allowing for higher and therefore more effective pulmonary concentrations without dose limiting
- 28 toxic effects.

29

30 **Objectives:** To assess the local tolerability, safety and pharmacokinetic parameters of HCQ

31 inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler.

32

Methods: 12healthy volunteers were trained in inhaling HCQ correctly. Local tolerability and safety
 were assessed by pulmonary function tests, ECG and recording adverse events. To estimate systemic
 exposure, serum samples were collected before and 0.5, 2 and 3.5 h after inhalation.

36

Results and discussion: Dry powder HCQ inhalations were well tolerated by the participants, except
for transient bitter taste in all participants and minor coughing irritation. There was no significant
change in QTc-interval or drop in FEV₁ post inhalation. The serum HCQ concentration remained
below 10 µg/L in all samples.

41

42 Conclusion: Inhaled dry powder HCQ is safe and well tolerated. Our data support further studies with
 43 inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy is warranted.

45 **1. INTRODUCTION**

In late December 2019 an outbreak of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), started in Wuhan, China, and caused the spread of corona virus disease 2019 (COVID-19) [1]. The WHO declared the epidemic of COVID-19 a pandemic on March 12th, 2020 [2]. The virus is still rapidly spreading with over 41 million cases and 1.1 million deaths reported worldwide in the second week of November 2020 [3]. Currently Europe is again facing a steep rise in incidence and is in its 'second wave' now autumn has come.

52

53 Given that this pandemic has a huge impact on healthcare systems, social life and economics, there is 54 an urgent need for treatment of COVID-19. Currently available treatment options are mostly used in 55 hospitalized patient: the anti-inflammatory drug dexamethasone and anti-viral nucleoside analog 56 prodrug remdesivir. These drugs reduce mortality and shorten time to recovery respectively [4, 5]. In 57 addition to an effective treatment there is also the need to be able to prevent and decrease 58 transmission in the general population and moreover in healthcare workers or other high-risk 59 groups. We are awaiting results from clinical trials with vaccines; as these will almost certainly not be 60 100% effective, alternatives should be investigated for both treatment in early disease and 61 prevention of transmission. Repositioning old drugs for use as antiviral or anti-inflammatory 62 treatment is an interesting strategy because the safety profile, side effects, posology and drug 63 interactions are already known which can speed up the trial program duration considerably.

Among those drugs is hydroxychloroquine sulphate (HCQ), which is mostly used in rheumatologic conditions because of its immune-modulatory effects [6, 7]. HCQ has proven to be effective in *in vitro* Vero cell systems infected with SARS-CoV-2 in two separate Chinese studies [8, 9]. Angiotensin converting enzyme 2 (ACE2) receptor expressing cells play an important role in the pathogenesis of SARS-CoV-2 infection, as the virus uses this receptor for entering the cell [8, 10-12]. HCQ impairs the terminal glycosylation of ACE2 and thereby inhibits cell-binding and consequently entry of the virus into the cell [13-15]. Furthermore, HCQ also blocks transport of SARS-CoV-2 from early endosomes to

71 endolysosomes, a requirement to release the viral genome [8, 9, 16]. Finally, HCQ has anti-72 inflammatory properties as it influences the generation of pro-inflammatory cytokines and 73 endosomal inhibition of toll-like receptors, which have a major role in innate immune response [8, 74 17-20]. Based on these in vitro findings oral HCQ was used abundantly worldwide in the beginning of 75 the COVID-19 pandemic, both off label and in clinical trials. Some observational studies showed 76 clinical benefit and antiviral effects [21-25] while others did not [26, 27] or were inconclusive [28, 77 29]. Currently both the FDA and EMA advice against the off-label use of oral HCQ based on the large 78 clinical RECOVERY trial that showed no beneficial effects on 28-day mortality [30]. The prospective 79 European DISCOVERY trial and WHO SOLIDARITY trial have discontinued the oral HCQ treatment 80 because of a lack of effect on mortality arms as well. The failing treatment with oral HCQ may be 81 explained by insufficient concentrations in alveolar epithelial cells due to its enormous volume of 82 distribution of 5500 L [31]. Raising the oral dose is not an option since this is limited by adverse or 83 even toxic effects, including the risk of cardiovascular toxicity (QTc prolongation).

84 Pulmonary administration of HCQ can be the solution to reach high local pulmonary concentrations 85 without systemic toxicity [32, 33]. For this purpose, we developed a dry powder formulation of HCQ 86 suitable for inhalation using the Cyclops dry powder inhaler. The Cyclops is a high dose disposable 87 inhaler that enables effective dispersion of up to 50 mg of drug in the preferred size range for 88 inhalation [34]. The aim of this study was to assess local tolerability and safety of increasing doses of 89 dry powder HCQ administered using the Cyclops to healthy volunteers. The chosen doses of 5 mg, 10 90 mg and 20 mg are comparable with known doses of inhaled nebulized HCQ and thus expected to be 91 safe [33, 35-38]

- 92
- 93
- 94

96 2. METHODS

97 Study design

98 This study was an open-label phase 1a single ascending dose study with twelve healthy volunteers. It 99 was performed at the University Medical Center Groningen (UMCG) location Beatrixoord (Groningen, 100 the Netherlands) between in September and October 2020. It included administration of HCQ dry 101 powder per inhalation using the Cyclops in single ascending doses of 5 mg, 10 mg, and 20 mg. In- and 102 exclusion criteria are listed in Table 1. The study was approved by the local medical ethical review 103 committee (METc UMCG, Groningen, The Netherlands, METc number 2020.168). The study was 104 performed according to the Helsinki declaration (Fortaleza, Brazil, 2013) and was registered at 105 clinicaltrials.gov (NCT04497519). The study was conducted with the written informed consent of all 106 participating subjects.

107 Study drug

108 The dry powder formulation of HCQ was developed at the department of Pharmaceutical Technology 109 and Biopharmacy of the University of Groningen. For the production of the study drug 110 hydroxychloroquine sulphate was obtained from Ofipharma BV (Ter Apel, the Netherlands). The HCQ 111 Cyclops was produced by PureIMS B.V. (Roden, the Netherlands). Each Cyclops contained a nominal 112 dose of 5 mg or 10 mg HCQ; the 20 mg dose was administered as 2 successive inhalations with 10 mg 113 of HCQ.

114 *Objectives and procedures*

The primary objective was to assess local tolerability and safety. Local tolerability was assessed by spirometry combined with active questioning about adverse events experienced by the participants. A drop of the forced expiratory volume in the first second (FEV₁) of 15% or more after inhalation of HCQ compared to baseline FEV₁ was considered clinically significant and critical to decide on proceeding with the next ascending dose. Spirometry was performed before inhalation (baseline)

120 and 35 minutes and 95 minutes after inhalation of HCQ according to the ATS/ERS guidelines [39]. 121 Adverse events were continually assessed during the study day. Cough for more than one hour or 122 any other reported adverse event that made either the physician or the participant decide to stop 123 participation was considered critical to decide on proceeding with the next ascending dose. ECGs 124 were performed to assess the QTc interval as safety parameter. An ECG was obtained at the 125 screening visit, before inhalation of the first dose and approximately 3.5 hours after each HCQ 126 inhalation. An observed QTc interval of more than 500 ms was also considered critical on proceeding 127 with the next ascending dose. All tolerability and safety endpoints were discussed with a Data Safety 128 Monitoring Board (DSMB) after all twelve participants completed a dose step before proceeding to 129 the next ascending dose.

130 The secondary objectives were to assess systemic exposure of HCQ and measurement of inspiratory 131 flow parameters. To determine the systemic exposure, blood samples were collected from an 132 intravenous indwelling cannula just before inhalation and 30 minutes, 2 hours and 3.5 hours after 133 inhalation of HCQ. These samples were analyzed using a validated liquid chromatography tandem 134 mass spectrometry (LC-MS/MS) method performed at the laboratory of the department of Clinical 135 Pharmacy and Pharmacology of the UMC Groningen (ISO15189:2012 (M170) certified). The limit of 136 quantification is 10 µg/L. The delivered dose was determined by subtracting the powder residue 137 inside the Cyclops after inhalation from the exact weighed dose pre inhalation. The powder residues 138 in the Cyclops were dissolved in demineralized water and the solutions were analyzed with a Thermo 139 Scientific spectrophotometer (Genesys 150 UV–VIS, The Netherlands) at a wavelength of 236.0 nm.

Prior to inhalation of the study drug, study participants received inhalation instructions followed by training regarding handling of the device and performing a correct inhalation maneuver. Training was done using an empty Cyclops connected to a laptop, with in-house developed software application (labVIEW, National Instruments, the Netherlands) for recording of and processing of flow curves generated through the device. When a series of consistent flow curves meeting the criteria for

good inhaler performance was obtained during training, a similarly instrumented Cyclops with HCQ
was handed to the participant. Inspiratory flow parameters were recorded during each drug
administration.

148 Data management and statistics

149 Study data were collected and managed using Research Electronic Data Capture (REDCap) [40,

150 41]. Statistical analysis was performed with SPSS version 23. Data from all eligible subjects who

151 received at least one dose of the study drug were included in analyses of safety. Data were

summarized using descriptive statistics. At each visit and timepoint, testing for differences in pre- to

153 post-dose changes in FEV1 (liters) and QTc interval were performed using the paired T-test or

154 Wilcoxon rank sum test. P values below 0.05 were considered statistically significant.

156 **RESULTS**

Twelve healthy volunteers were enrolled, and all completed the study. See table 2 for all patient characteristics. All participants had normal baseline QTc interval and G6PD-deficiency was excluded in all participants. At the screenings visit pregnancy was excluded in female participants.

160 There were no serious adverse events observed during or after the study (see table 3). None of the 161 participants had cough longer than the pre-defined safety period of one hour. Minor complaints of 162 cough were reported four times, each in a different participant, directly after inhalation of HCQ; two 163 times after a dose of 10 mg HCQ and two times after a dose of 20 mg HCQ. Complaints varied from 164 experience of an itchy or tickling sensation in the throat to a single or a few observed coughs that were self-limiting. Two participants reported minimal dyspnea which disappeared after coughing or 165 166 spontaneously within 4 minutes after inhalation. All participants mentioned bitter taste after 167 inhalation. In most participants this lasted for 5-10 minutes, but one participant reported the bitter 168 taste for 2 hours. Participants were advised to rinse their mouth with water or eat something after 169 the dose was administered with satisfying effect. Two participants had complaints of slight nausea 170 relating to the bitter taste; one for 5 minutes after a dose of 5 mg HCQ and one for 70 minutes after 171 a dose of 10 mg HCQ. Sore throat was reported by three participants. Two participants developed 172 symptoms of upper respiratory tract infection in the following days of which one tested positive by 173 PCR nasopharyngeal swab for SARS-CoV-2 two days after the last study visit. One participant 174 experienced some hoarseness, which disappeared after drinking some water. Two other adverse 175 events were recorded. One participant with an intrauterine contraceptive device in situ experienced 176 minor spotting two days after inhalation of HCQ after both the 5 mg and 10 mg dose. This is not 177 mentioned as a known side-effect of oral HCQ [42]. One participant mentioned dry eyes once at a 178 dose of 20 mg, which seemed to be related to the dry hospital environment and not to 179 administration of the study drug.

180	None of the participants showed a significant drop in FEV_1 ($\geq 15\%$) at any time point after HCQ
181	administration (see table 4). A maximum drop of -7.51% was observed 95 minutes after inhalation of
182	5 mg HCQ. This participant mentioned a sort of burning sensation at the chest at that moment as
183	well but no dyspnea, something he also recognizes while running.
184	None of the participants had a QTc prolongation \geq 500, nor even \geq 450 ms. Mean QTc interval was
185	412 ± 21 ms (range 384-441) at baseline. This did not change significantly 3.5 hour after inhalation of
186	5 mg, 10 mg and 20 mg HCQ, respectively (see table 5).
187	In all participants, the serum HCQ concentrations sampled 30 minutes, 2 hours and 3.5 hours, were
188	below the detection level of 10 $\mu\text{g/L}$ irrespective of dose. The mean delivered dose was 3.16 mg
189	(63%) after administration of 5 mg HCQ, 6.95 mg (70%) after administration of 10 mg HCQ and 14.86
190	mg (75%) after administration of 20 mg HCQ. Based on the recorded inspiratory flow parameters, all

- 191 participants correctly performed the inhalation maneuvers.
- 192

194 **DISCUSSION**

Pulmonary administration of HCQ for early COVID-19 treatment or prevention in post-exposed individuals might be better than oral administration of HCQ due to the pharmacological properties of HCQ. Hypothetically, it can reach higher pulmonary concentrations compared to oral HCQ while using much lower doses and exerting lower systemic exposure. This phase 1 study with inhaled HCQ with three different doses showed good local tolerability and safety without significant systemic side effects.

201

202 Coughing was reported four times out of a total of 36 administered doses (11%) in four different 203 participants and was very mild in severity. Coughing is often reported after inhalation of 204 antimicrobials by both wet nebulization and dry powder inhalation, with data mainly available from 205 cystic fibrosis patients treated with colistin or tobramycin. In general, this population cough is more 206 frequently reported after dry powder inhalation (ranging from 75% - 90%) than after nebulization 207 (ranging from 31% - 78%) in these patients, although some studies found no differences [43-45]. The 208 trigger for both cough and probably bitter taste is deposition of the drug in the oropharynx. This 209 could be expected since HCQ is a quinoline known for its extremely bitter taste (249 on a bitter scale 210 compared to caffeine at 46) [46]. However, the majority reported that the taste was not disturbing 211 since the participants were warned beforehand, it was minor, and it disappeared within a few 212 minutes after HCQ inhalation or even faster when rinsing the mouth with water or eating something 213 directly after inhalation.

214

Bronchus obstruction was not a problem after inhalation of HCQ dry powder; in none of the twelve participants experienced a drop in FEV₁ of more than 15%. The maximum drop was 7.5 % compared to baseline and this was not accompanied by dyspnea. One participant did mention a light burning sensation at the chest at that moment, something he also experienced while running. Although not formerly diagnosed, this participant might suffer from a mild exercise induced asthma. Nevertheless,

220 we believe that HCQ dry powder can be used safely in asthma patients as well, since aerosolized HCQ 221 has been applied in a phase I clinical study to assess safety for use in asthma and was concluded to 222 be safe and well tolerated in 31 healthy individuals in doses up to 20 mg daily for 7 days [33, 36]. In 223 2006, a phase 2 clinical trial with aerosolized HCQ as anti-inflammatory treatment for patients with 224 asthma followed. A dose of 20 mg daily was tolerated for up to 21 days, but it failed to meet the 225 primary clinical endpoints for effective asthma treatment; relative improvement in FEV₁ compared to 226 baseline was not statistically significant after treatment compared to placebo [33, 37]. None of these 227 participants had significant ECG changes and side effects consisted of headache and nausea only [33, 228 36, 37].

229

230 HCQ serum concentrations were below the quantification limit of 10 μ g/L in all participants and 231 irrespective of dose or timepoints. Possibly our timing of blood sampling was sub optimal. The 232 timepoints were chosen based on the absorption rate after oral administration, because data after 233 inhalation were not available at that time. If the maximum concentration (C_{max}) occurs very shortly 234 after inhalation (T_{max}) , we might have missed this peak concentration with our first blood sample 235 drawn after 30 minutes. This is supported by the only other available pharmacokinetic data from a 236 phase I clinical trial with aerosolized HCQ that came available after our study protocol was 237 developed. Fifteen healthy volunteers inhaled single doses of 5, 10 or 20 mg HCQ. Reported HCQ 238 serum concentrations were mean C_{max} between 22 and 69 μ g/L with an early T_{max} within 2-3 minutes. 239 The reported systemic exposure was very low $(7-54 \ \mu g^*h/L)$, suggesting elimination within 30 240 minutes [33].

Local lung concentrations are expected to be higher after inhalation of HCQ compared to oral
administration, even though the highest dose of inhaled HCQ in this study (20 mg) is only a fraction
of the usual oral HCQ dose (200-800 mg). For example, if the delivered dose of 14.86 mg
homogeneously distributes over the lung tissue (843 mL) [47], then a lung tissue HCQ concentration
of approximately 40 µM would be achieved. Preliminary results from our own experiments in

246 primary human epithelial cells indicate that HCQ concentrations of approximately 20 to 40 μ M do 247 result in a significant reduction in viral load after SARS-CoV-2 infection (manuscript in preparation). 248 This is in contrast to the lack of antiviral effect found by Mulay et al. at an HCQ concentration of only 249 10 μM, which because of the fourfold lower concentration than potentially achievable after HCQ 250 inhalation seems to hold less relevance [48]. Based on these considerations, effective concentrations 251 can potentially be achieved in lung tissue after inhalation of 20 mg HCQ. These high HCQ 252 concentrations and the superior potential of inhaled over oral HCQ should be the new starting point 253 of any further clinical studies on the activity of HCQ against SARS-CoV-2.

254 The concerns about cardiotoxicity of oral HCQ, a well-known drug and generally considered to be 255 safe and well tolerated, were magnified by a large retrospective observational study that reported a 256 strong association between the use of HCQ and ventricular tachycardia and death in hospitalized 257 COVID-19 patients [50]. However, this paper was retracted soon after publication because of 258 concerns about the data validity [49, 50]. White et al. state that a lot of confusion has arisen by 259 extrapolating long-term risks of myocardial damage with chronic dosing to short-term exposures, 260 thereby overestimating the risk of ventricular arrhythmias [31]. Our study shows that systemic 261 exposure after inhalation is very low, which is a positive result regarding the risk of systemic toxicity. 262 Also, the concerns for any other possible systemic adverse event should be tempered because of 263 these results.

A limitation of our study is that only serum concentrations are measured and not local pulmonary concentrations. So far, only in vitro experiments on Vero cells have shown efficacy and data from human pulmonary concentrations and thus local efficacy are lacking [8, 9]. Since in our study no systemic exposure of HCQ was detected for all participants and for all doses, it is not expected that systemic side effects will occur and HCQ might therefore also be used in patients of older age and with comorbidities.

- 270 In conclusion, HCQ inhalation using the Cyclops is safe and generally well tolerated by healthy
- volunteers, except for minor cough and bitter taste. These positive results and the superior safety

and efficacy potential of inhaled over oral HCQ strongly encourage the execution of further clinical

- studies with inhaled HCQ to battle this COVID-19 pandemic.
- 274

275 Acknowledgements

- 276 We thank Marieke van Rossum and Marina Zenina for their help in the execution of this study.
- 277

278 Funding Sources:

- 279 The production, labelling and distribution of the HCQ dry powder Cyclops inhalers was provided free
- 280 of charge by PureIMS.
- All other funding was supplied by the institutions of the participating authors at University of
- 282 Groningen and University Medical Center Groningen

- 284 Conflict of interest:
- 285 YdR: no conflicts of interest
- 286 PH: The employer of PH has a royalty agreement with AstraZeneca on the sales of the Genuair
- 287 Inhaler; In addition, PH has a patent WO2015NL50413 20150605 licensed.
- 288 **MS**: no conflict of interest
- 289 **FG**: FG is employed by PureIMS, the manufacturer of the Cyclops inhaler.
- 290 MB: no conflicts of interest

- 291 **IS**: no conflicts of interest
- 292 HK: no conflict of interest
- 293 EF: The employer of HWF has a license agreement with PureIMS on the Cyclops patent
- 294 (WO2015/187025)
- 295 **OA:** no conflicts of interest

296 References

~~~		
297	1.	Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J
298	2	Med, 2020. <b>382</b> (8): p. 727-733.
299	2.	WHO, <u>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-</u>
300	2	<u>sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4</u> .
301	3.	https://coronavirus.jhu.edu/map.html, COVID-19 Map - Johns Hopkins Coronavirus Resource
302		Center. Accessed October 22th, 2020.
303 304	4.	Beigel, J.H., et al., <i>Remdesivir for the Treatment of Covid-19 - Final Report</i> . N Engl J Med,
304 305	F	2020. Group Will O.B.F.A.f.C. T.W. et al. Association Between Administration of Systemic
	5.	Group, W.H.O.R.E.A.f.CT.W., et al., Association Between Administration of Systemic
306		Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Meta-analysis.
307	6	JAMA, 2020.
308	6.	Rynes, R.I., <i>Hydroxychloroquine treatment of rheumatoid arthritis</i> . Am J Med, 1988. <b>85</b> (4A):
309	_	p. 18-22.
310	7.	Schrezenmeier, E. and T. Dorner, <i>Mechanisms of action of hydroxychloroquine and</i>
311	-	chloroquine: implications for rheumatology. Nat Rev Rheumatol, 2020. <b>16</b> (3): p. 155-166.
312	8.	Liu, J., et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in
313	_	inhibiting SARS-CoV-2 infection in vitro. Cell Discov, 2020. 6: p. 16.
314	9.	Yao, X., et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of
315		Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2
316		(SARS-CoV-2). Clin Infect Dis, 2020.
317	10.	Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-
318		induced lung injury. Nat Med, 2005. <b>11</b> (8): p. 875-9.
319	11.	Zhou, D., S.M. Dai, and Q. Tong, COVID-19: a recommendation to examine the effect of
320		hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother, 2020.
321	12.	Subbarao, K., et al., Prior infection and passive transfer of neutralizing antibody prevent
322		replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J
323		Virol, 2004. <b>78</b> (7): p. 3572-7.
324	13.	Pahan, P. and K. Pahan, Smooth or Risky Revisit of an Old Malaria Drug for COVID-19? J
325		Neuroimmune Pharmacol, 2020. <b>15</b> (2): p. 174-180.
326	14.	Ledford, H., How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose
327		<i>treatments</i> . Nature, 2020. <b>580</b> (7803): p. 311-312.
328	15.	Stower, H., <i>Virological assessment of SARS-CoV-2</i> . Nat Med, 2020. <b>26</b> (4): p. 465.
329	16.	Mingo, R.M., et al., Ebola virus and severe acute respiratory syndrome coronavirus display
330		late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining
331		<i>step.</i> J Virol, 2015. <b>89</b> (5): p. 2931-43.
332	17.	Devaux, C.A., et al., New insights on the antiviral effects of chloroquine against coronavirus:
333		what to expect for COVID-19? Int J Antimicrob Agents, 2020: p. 105938.
334	18.	Costedoat-Chalumeau, N., et al., Hydroxychloroquine: a multifaceted treatment in lupus.
335		Presse Med, 2014. <b>43</b> (6 Pt 2): p. e167-80.
336	19.	Kuznik, A., et al., Mechanism of endosomal TLR inhibition by antimalarial drugs and
337		<i>imidazoquinolines</i> . J Immunol, 2011. <b>186</b> (8): p. 4794-804.
338	20.	Gies, V., et al., Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Front Immunol,
339		2020. <b>11</b> : p. 1409.
340	21.	Gao, J., Z. Tian, and X. Yang, Breakthrough: Chloroquine phosphate has shown apparent
341		efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends,
342		2020. <b>14</b> (1): p. 72-73.
343	22.	Gautret, P., et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results
344		of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020: p. 105949.
345	23.	Arshad, S., et al., Treatment with hydroxychloroquine, azithromycin, and combination in
346		patients hospitalized with COVID-19. Int J Infect Dis, 2020. 97: p. 396-403.

347	24.	Cortegiani, A., et al., A systematic review on the efficacy and safety of chloroquine for the
348		<i>treatment of COVID-19.</i> J Crit Care, 2020. <b>57</b> : p. 279-283.
349	25.	Lammers, A.J.J., et al., Early Hydroxychloroquine but not Chloroquine use reduces ICU
350		admission in COVID-19 patients. Int J Infect Dis, 2020.
351	26.	Mahévas, M., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised
352		for COVID-19 infection and requiring oxygen: Results of a study using routinely collected data
353		to emulate a target trial. MedRxiv, 2020.
354	27.	Geleris, J., et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with
355		<i>Covid-19.</i> N Engl J Med, 2020.
356	28.	Tang, W., et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus
357		disease 2019: open label, randomised controlled trial. BMJ, 2020. <b>369</b> : p. m1849.
358	29.	Chen, Z., Efficacy of hydroxychloroquine and azithromycin as a treatment of COVID-19: results
359		of a randomized clinical trial. medRxiv, 2020.
360	30.	Group, R.C., et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl
361		J Med, 2020.
362	31.	White, N.J., et al., COVID-19 prevention and treatment: A critical analysis of chloroquine and
363		hydroxychloroquine clinical pharmacology. PLoS Med, 2020. <b>17</b> (9): p. e1003252.
364	32.	Klimke, A., et al., Hydroxychloroquine as an aerosol might markedly reduce and even prevent
365		severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses, 2020. <b>142</b> : p. 109783.
366	33.	Kavanagh, O., et al., Inhaled hydroxychloroquine to improve efficacy and reduce harm in the
367		treatment of COVID-19. Med Hypotheses, 2020. <b>143</b> : p. 110110.
368	34.	Hoppentocht, M., et al., The Cyclops for pulmonary delivery of aminoglycosides; a new
369		<i>member of the Twincer family</i> . Eur J Pharm Biopharm, 2015. <b>90</b> : p. 8-15.
370	35.	Dayton, F., Development of an inhaled hydroxychloroquine sulfate product using the AERx
371		system to treat asthma. Respiratory Drug Delivery 2006.
372	36.	Wire M, N.N., Corporation A, Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical
373		Program of Novel Treatment for Asthma. 2006.
374	37.	Wire M, N.N., Corporation A, Aradigm Announces the Results of the AERx HCQ Asthma Phase
375		2 a Study. 2006.
376	38.	Garcia-Luzardo Mdel, R., A.J. Aguilar-Fernandez, and G. Cabrera-Roca, [Idiopathic pulmonary
377		haemosiderosis in childhood: a good response to systemic steroids, inhaled
378		hydroxychloroquine and budesonide]. Arch Bronconeumol, 2010. <b>46</b> (11): p. 612-3.
379	39.	Graham, B.L., et al., Standardization of Spirometry 2019 Update. An Official American
380		Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care
381		Med, 2019. <b>200</b> (8): p. e70-e88.
382	40.	Harris, P.A., et al., The REDCap consortium: Building an international community of software
383		<i>platform partners</i> . J Biomed Inform, 2019. <b>95</b> : p. 103208.
384	41.	Harris, P.A., et al., Research electronic data capture (REDCap)a metadata-driven
385		methodology and workflow process for providing translational research informatics support. J
386		Biomed Inform, 2009. <b>42</b> (2): p. 377-81.
387	42.	Thomson Reuters (Healthcare). <i>Micromedex® 2.0</i> 11-16-2020]; Available from:
388		http://www.thomsonhc.com
389	43.	Harrison, M.J., et al., Inhaled versus nebulised tobramycin: a real world comparison in adult
390		<i>cystic fibrosis (CF)</i> . J Cyst Fibros, 2014. <b>13</b> (6): p. 692-8.
391	44.	Akkerman-Nijland, A.M., et al., Colistin dry powder inhalation with the Twincer: An effective
392		and more patient friendly alternative to nebulization. PLoS One, 2020. 15(9): p. e0239658.
393	45.	Uttley, L., et al., Systematic review of the dry powder inhalers colistimethate sodium and
394		tobramycin in cystic fibrosis. Eur Respir Rev, 2013. <b>22</b> (130): p. 476-86.
395	46.	Pauli, E., et al., Evaluation of an Immediate-Release Formulation of Hydroxychloroquine
396		Sulfate With an Interwoven Pediatric Taste-Masking System. J Pharm Sci, 2020. <b>109</b> (4): p.
397		1493-1497.

398	47.	Armstrong, J.D., et al., Lung tissue volume estimated by simultaneous radiographic and
399		helium dilution methods. Thorax, 1982. <b>37</b> (9): p. 676-9.
400	48.	Mulay, A., et al., SARS-CoV-2 infection of primary human lung epithelium for COVID-19
401		modeling and drug discovery. bioRxiv, 2020.
402	49.	Mehra, M.R., et al., RETRACTED: Hydroxychloroquine or chloroquine with or without a
403		macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020.
404	50.	James Watson on the behalf of 201 signatories. An open letter to Mehra et al and the Lancet
405		(Version 4). Available from: https://zenodo.org/record/3862789#.X5wzpNxYYRA, 2020.
		( · · · · · · · · · · · · · · · · · · ·
406		
407		
408		
409		
410		
411		
412		
413		
414		
415		
416		
417		
418		
419		
420		
421		
422		
423		
424		

Table 1. In- and exclusion criteria

### Inclusion criteria

Healthy volunteer

Age 18-65 years

Obtained written informed consent

# **Exclusion criteria**

Pregnancy or breastfeeding

Contra-indication to (hydroxy)chloroquine or quinine (allergic reaction, prolonged QTc-interval (>

450 msec), long-QT syndrome (LQTS), retinopathy, epilepsia, myasthenia gravis, G6PD-deficiency)

Concurrent use of ciclosporin, digoxin, ritonavir, tamoxifen or tranylcypromine.

Concurrent use of high risk QTc prolongating drugs (amiodarone, erythromycin (daily dose > 1000

mg) or sotalol)

COVID-19 like symptoms, such as fever, couch, or sore throat; only by history taking.

Table 2. Participant characteristics

	N (%) or Mean (range)
Sex (male / female), N (%)	9 (75) / 3 (25)
Age (years)	30 (20 – 53)
FEV1 predicted (%)	101 (90 - 112)
BMI (kg/m²)	26.2 (21.8 – 38.5)
Non-smoking / Ex-smoking /	4 (33) /4 (33)/ 4 (33)
Current smoker, N (%)	

Percentage of patients

		· · · · · · · · · · · · · · · · · · ·
Cough	11.1%	33.3%
Dyspnea	5.6%	16.7%
Bitter taste	100%	100%
Nausea	5.6%	16.7%
Sore throat /	8.3%	25%
respiratory infection		
Hoarseness	2.8%	8.3%
Spotting	5.6%	8.3%
Dry eyes	2.8%	8.3%

# Table 3. Reported adverse events out of 36 HCQ administrations by inhalation

Percentage of total administrations

Adverse events

Dose	Change in FEV1	P value	Change in FEV1	P value
	from baseline 35		from baseline 95	
	min post inhalation		min post inhalation	
5 mg	-0.98 ± 1.98	0.123	-1.21 ± 2.91	0.167
нсq	(-5.44 - +1.90)		(-7.51 – +2.44)	
10 mg	-0.21 ± 3.2	0.640	0.21 ± 2.74	0.097
HCQ	(-7.30 – +3.79)		(-5.31 – +4.66)	
20 mg	-0.98 ± 1.98	0.123	-1.21 ± 2.91	0.167
нсq	(-5.44 – +1.90)		(-7.51 – +2.44)	

Table 4. change in FEV1 post inhalation compared to baseline in %: mean ± SD and range

Table 5. Change in QTc time in ms

3,5 h after	P value
administration	
412 ± 21 ms	
(range 384-441)	
407 ± 19 ms (range	0.538
383-439)	
414 ± 15 ms	0.736
(range 392-447)	
409 ± 12 ms (range	0.648
381-423)	
	administration 412 ± 21 ms (range 384-441) 407 ± 19 ms (range 383-439) 414 ± 15 ms (range 392-447) 409 ± 12 ms (range